DDMODEL00000008: Rocchetti_2013_oncology_TGI_combo

  public model
Short description:
PKPD model of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts
PharmML 0.8.x (0.8.1)
  • Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
  • Rocchetti M, Germani M, Del Bene F, Poggesi I, Magni P, Pesenti E, De Nicolao G
  • Cancer chemotherapy and pharmacology, 5/2013, Volume 71, Issue 5, pages: 1147-1157
  • Pharmacokinetics and Modeling, Accelera S.r.l., Nerviano, MI, Italy. Università degli Studi di Pavia, Pavia, Italy.
  • PURPOSE: Pharmacokinetic-pharmacodynamic (PK-PD) models able to predict the action of anticancer compounds in tumor xenografts have an important impact on drug development. In case of anti-angiogenic compounds, many of the available models show difficulties in their applications, as they are based on a cell kill hypothesis, while these drugs act on the tumor vascularization, without a direct tumor cell kill effect. For this reason, a PK-PD model able to describe the tumor growth modulation following treatment with a cytostatic therapy, as opposed to a cytotoxic treatment, is proposed here. METHODS: Untreated tumor growth was described using an exponential growth phase followed by a linear one. The effect of anti-angiogenic compounds was implemented using an inhibitory effect on the growth function. The model was tested on a number of experiments in tumor-bearing mice given the anti-angiogenic drug bevacizumab either alone or in combination with another investigational compound. Nonlinear regression techniques were used for estimating the model parameters. RESULTS: The model successfully captured the tumor growth data following different bevacizumab dosing regimens, allowing to estimate experiment-independent parameters. A combination model was also developed under a 'no-interaction' assumption to assess the effect of the combination of bevacizumab with a target-oriented agent. The observation of a significant difference between model-predicted and observed tumor growth curves was suggestive of the presence of a pharmacological interaction that was further accommodated into the model. CONCLUSIONS: This approach can be used for optimizing the design of preclinical experiments. With all the inherent limitations, the estimated experiment-independent model parameters can be used to provide useful indications for the single-agent and combination regimens to be explored in the subsequent development phases.
Paolo Magni
Context of model development: Combination Therapy Dose Selection; Candidate Comparison, Selection, Human Dose Prediction;
Model compliance with original publication: Yes;
Model implementation requiring submitter’s additional knowledge: No;
Modelling context description: PURPOSE: Pharmacokinetic-pharmacodynamic (PK-PD) models able to predict the action of anticancer compounds in tumor xenografts have an important impact on drug development. In case of anti-angiogenic compounds, many of the available models show difficulties in their applications, as they are based on a cell kill hypothesis, while these drugs act on the tumor vascularization, without a direct tumor cell kill effect. For this reason, a PK-PD model able to describe the tumor growth modulation following treatment with a cytostatic therapy, as opposed to a cytotoxic treatment, is proposed here. METHODS: Untreated tumor growth was described using an exponential growth phase followed by a linear one. The effect of anti-angiogenic compounds was implemented using an inhibitory effect on the growth function. The model was tested on a number of experiments in tumor-bearing mice given the anti-angiogenic drug bevacizumab either alone or in combination with another investigational compound. Nonlinear regression techniques were used for estimating the model parameters. RESULTS: The model successfully captured the tumor growth data following different bevacizumab dosing regimens, allowing to estimate experiment-independent parameters. A combination model was also developed under a 'no-interaction' assumption to assess the effect of the combination of bevacizumab with a target-oriented agent. The observation of a significant difference between model-predicted and observed tumor growth curves was suggestive of the presence of a pharmacological interaction that was further accommodated into the model. CONCLUSIONS: This approach can be used for optimizing the design of preclinical experiments. With all the inherent limitations, the estimated experiment-independent model parameters can be used to provide useful indications for the single-agent and combination regimens to be explored in the subsequent development phases.;
Modelling task in scope: estimation;
Nature of research: Preclinical development; In vivo;
Therapeutic/disease area: Oncology;
Annotations are correct.
This model is not certified.
  • Model owner: Paolo Magni
  • Submitted: Sep 26, 2014 11:18:04 AM
  • Last Modified: Oct 10, 2016 7:53:05 PM
Revisions
  • Version: 6 public model Download this version
    • Submitted on: Oct 10, 2016 7:53:05 PM
    • Submitted by: Paolo Magni
    • With comment: Edited model metadata online.
  • Version: 4 public model Download this version
    • Submitted on: May 24, 2016 11:17:40 PM
    • Submitted by: Paolo Magni
    • With comment: Updated model annotations.
  • Version: 3 public model Download this version
    • Submitted on: Dec 10, 2015 10:37:36 PM
    • Submitted by: Paolo Magni
    • With comment: Edited model metadata online.
  • Version: 1 public model Download this version
    • Submitted on: Sep 26, 2014 11:18:04 AM
    • Submitted by: Paolo Magni
    • With comment: Import of Rocchetti_2013_oncology_TGI_antiangiogenic_combo

Name

Generated from MDL. MOG ID: rocchetti2013

Independent Variables

T

Function Definitions

proportionalError:realproportional:realf:real=proportionalf

Parameter Model: pm

Random Variables

eps_RES_Wvm_err.DV~Normal2mean=0var=1

Population Parameters

POP_LAMBDA0
POP_LAMBDA1
POP_W0
POP_K1
POP_K2
POP_IC50
POP_IC50COMBO
POP_KA_A
POP_KE_A
POP_FV1_A
POP_KA_B
POP_KE_B
POP_K21
POP_K12
POP_FV1_B
POP_EMAX
CV

Individual Parameters

LAMBDA0=pm.POP_LAMBDA0
LAMBDA1=pm.POP_LAMBDA1
W0=pm.POP_W0
K1=pm.POP_K1
K2=pm.POP_K2
IC50=pm.POP_IC50
IC50COMBO=pm.POP_IC50COMBO
KA_A=pm.POP_KA_A
KE_A=pm.POP_KE_A
FV1_A=pm.POP_FV1_A
KA_B=pm.POP_KA_B
KE_B=pm.POP_KE_B
K21=pm.POP_K21
K12=pm.POP_K12
FV1_B=pm.POP_FV1_B
EMAX=pm.POP_EMAX

Structural Model: sm

Variables

PSI=20
C1_A=sm.Q1_Apm.FV1_A
C1_B=sm.Q1_Bpm.FV1_B
K2INH=pm.K21-sm.C1_Asm.C1_A+pm.IC50COMBO
WTOT=sm.Z0+sm.Z1+sm.Z2+sm.Z3
TQ0_A=-pm.KA_Asm.Q0_AQ0_AT=0=0
TQ1_A=pm.KA_Asm.Q0_A-pm.KE_Asm.Q1_AQ1_AT=0=0
TQ0_B=-pm.KA_Bsm.Q0_BQ0_BT=0=0
TQ1_B=pm.KA_Bsm.Q0_B-pm.K12+pm.KE_Bsm.Q1_B+pm.K21sm.Q2_BQ1_BT=0=0
TQ2_B=pm.K12sm.Q1_B-pm.K21sm.Q2_BQ2_BT=0=0
TZ0=pm.LAMBDA0sm.Z01+sm.WTOTpm.LAMBDA0pm.LAMBDA1sm.PSI1sm.PSI1-pm.EMAXsm.C1_Asm.C1_A+pm.IC50-sm.K2INHsm.C1_Bsm.Z0Z0T=0=pm.W0
TZ1=sm.K2INHsm.C1_Bsm.Z0-pm.K1sm.Z1Z1T=0=0
TZ2=pm.K1sm.Z1-pm.K1sm.Z2Z2T=0=0
TZ3=pm.K1sm.Z2-pm.K1sm.Z3Z3T=0=0

Observation Model: om1

Continuous Observation

Y=sm.WTOT+proportionalErrorproportional=pm.CVf=sm.WTOT+pm.eps_RES_W

External Dataset

OID
nm_ds
Tool Format
NONMEM

File Specification

Format
csv
Delimiter
comma
File Location
Simulated_rocchetti2013_data.csv

Column Definitions

Column ID Position Column Type Value Type
ID
1
id
int
TIME
2
idv
real
DV
3
dv
real
AMT
4
dose
real
CMT
5
cmt
int
MDV
6
mdv
int

Column Mappings

Column Ref Modelling Mapping
ID
vm_mdl.ID
TIME
T
DV
om1.Y
AMT
{sm.Q0_AifCMT=1AMT>0sm.Q0_BifCMT=2AMT>0

Estimation Step

OID
estimStep_1
Dataset Reference
nm_ds

Parameters To Estimate

Parameter Initial Value Fixed? Limits
pm.POP_LAMBDA0
0.14
true
pm.POP_LAMBDA1
0.129
true
pm.POP_W0
0.062
true
pm.POP_K1
3.54
true
pm.POP_K2
0.221
true
pm.POP_IC50
2.02
true
pm.POP_IC50COMBO
7
false
0
pm.POP_KA_A
2.69
true
pm.POP_KE_A
0.115
true
pm.POP_FV1_A
8.4
true
pm.POP_KA_B
18.8
true
pm.POP_KE_B
49.2
true
pm.POP_K21
10.4
true
pm.POP_K12
141.1
true
pm.POP_FV1_B
0.469
true
pm.POP_EMAX
1
true
pm.CV
0.1
false
0

Operations

Operation: 1

Op Type
generic
Operation Properties
Name Value
algo
foce

Step Dependencies

Step OID Preceding Steps
estimStep_1
 
Help